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Treatment of epilepsy following rejection of epilepsy 
surgery 
PETER WOLF 
Epilepsiezentrum Bethel, Bethelweg 15, 33617 Bielefeld, Germany 
Important progress has been made with the development of both surgical and medicinal treatment of epilepsy but these two 
developments are rarely seen in a common perspective. Today epilepsy surgery should be discussed with the patient when 
a reasonable degree of pharmacoresistance has been established, and the chances of an operation clearly outweigh its risks. 
At that time, there will still be a number of pharmacological options. 
A study of 15 patients who were evaluated for at least four years after surgery had been considered but rejected after 
intensive monitoring, pharmacological pursuit was successful in eight, and failed in seven. The successfully treated patients 
comprise three who became seizure free, and one with isolated auras as the only persisting seizure type. The successful 
regimens were highly individual, stretching from monotherapies to one four-drug combination. 
The idea of presenting this small series is not to promote or establish any therapeutic strategies and guidelines but, rather, 
to draw attention to a neglected interface between surgical and medicinal procedures, and to increase awareness that epilepsy 
therapy will still be most successful when it is seen as a whole, and must not be split up into competing ideologies, 
Concerns are not well founded that epilepsy surgery may be seen as the last hope for pharmacoresistant patients. and that, 
if surgery is declined, a loss of this hope may be intolerable to the patient. 
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INTRODUCTION 
Epilepsy surgery, although a suitable approach for 
only a minority of patients, has, during the last 
decade, appeared to many as the most important fron- 
tier in epileptology. This view, however, has been 
radically contested in this journal’. At the same 
time, we are experiencing the advent of a consid- 
erable number of new antiepileptic drugs with a di- 
versity of mechanisms of action which are introduced 
with high hopes for therapeutic improvements. In pa- 
tients whose seizures are resistant to traditional drugs 
they seem, however, only rarely to provide complete 
seizure control, the ultimate aim of epilepsy therapy. 
These developments are rarely seen together in 
a common perspective. There are wide discrepan- 
cies in the approach to new developments in these 
two therapeutic fields, for example, in the role ac- 
corded to randomized controlled trials’. In addition, 
neither of these strategies seem to take any notice 
of alternative, non-drug non-surgery approaches2-5. 
We should be concerned with the possibility 
that the various strategies of epilepsy treatment 
drift apart to form separate therapeutic cultures- 
certainly not a development in the patients’ interest. 
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Another concern is that epilepsy surgery is of- 
ten regarded as a last hope for therapy-resistant pa- 
tients with epilepsy, and a frequent concern of people 
who care about such patients is what may happen if 
that hope also fails. It should be recalled, however, 
that there is no absolute and ultimate therapy resis- 
tance, and the number of possible therapeutic strate- 
gies is increasing with the advent of new drugs. To- 
day, epilepsy surgery is not considered when no phar- 
maceutical option whatsoever is open but when stan- 
dard pharmacotherapy has failed, and chances of find- 
ing a successful conservative treatment6 are small. 
There is no universally accepted guideline about 
the extent of pharmacoresistance which should be 
reached before considering surgery. In particular, 
there is no consensus about the role of the new 
AEDs in this respect, or of the usefulness of try- 
ing drug combinations before going to surgery. 
Most of the centres performing epilepsy surgery 
therefore seem to follow their own policy, and it 
has not even become routine yet-as would be 
desirable-for the centres to publish their criteria. 
At our centre we request that three first-choice 
antiepileptic drugs (AEDs) should have been admin- 
istered, in monotherapy, in doses increasing until 
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first toxic side-effects appeared, and did not con- 
trol the seizures, at least not those seizures which 
are disabling or a challenge to the patients’ qual- 
ity of life7. Usually, in that case, the possibility of 
epilepsy surgery will be discussed, and presurgical 
intensive monitoring will be proposed. However, not 
all of these patients will accept this suggestion. Some 
are strictly opposed to the idea of brain surgery, oth- 
ers will first ask for further drug trials, and still oth- 
ers will accept intensive monitoring on the expressed 
condition that the ultimate decision will only be taken 
afterwards. The above selection process ensures that 
there will still be pharmacotherapeutic options in the 
case where surgery is declined following intensive 
monitoring. 
In that case, there are again no guidelines for ther- 
apy, and there are to my knowledge no reports of pa- 
tients in that situation. This paper is a report of those 
15 patients who have been under the authors treat- 
ment for a period of at least four years after epilepsy 
surgery was first considered, and then rejected. The 
idea of presenting this small series is not to promote 
or establish any therapeutic strategies and guidelines 
but, rather, to draw attention to a neglected interface 
between surgical and medicinal procedures, and to 
increase awareness that epilepsy therapy will still be 
most successful when it is seen as a whole, and must 
not be split up into competing ideologies. 
PATIENTS AND METHODS 
The demographic and diagnostic data are summa- 
rized in Table 1. All patients had focal (partial onset) 
seizures. All underwent some type of non-invasive or 
invasive intensive EEG monitoring in view of possi- 
ble epilepsy surgery (Table 2). These investigations 
took place between April 1987 and March 1992, and 
the patients have prospectively been followed since 
then. In two instances, the evaluation was done else- 
where, and I first met the patients afterwards. All 
others were in my treatment before, and intensive 
monitoring had been decided between us following 
failure of pharmacotherapy. All but one of the latter 
13 evaluations were performed in our centre. Non- 
compliance as a reason for pharmacoresistance had 
been ruled out in all 15 cases by post-ictal assess- 
ments of AED serum levels. 
In six cases, invasive further studies, and in another 
six, a surgical intervention had been discussed with 
the patients whereas, in the remaining three, the re- 
sults of the evaluation had discouraged any further 
steps. Further procedures were declined at least tem- 
porarily by the patients and their relatives in seven 
cases and by the hospital team in six cases, with two 
immediate consensus decisions (Table 2). 
Table 1: 
Patient overview 
Females 9 
Males 6 
Age at epilepsy onset 14.3 yr (145) 
Age at investigation 33.7 yr (18-50) 
Diagnoses: 
Temporal lobe epilepsy 6 
of these, bilateral 3 
Extratemporal epilepsy 5 
Focal with unclear localization 1 
With focal and generalized signs 3 
Aetiological and pathogenetic factors 
Febrile convulsions 3 
Positive family history 2 
Encephalitis 2 
Undefined lesion 2 
Oligodendroglioma 1 
Vascular malformation 1 
Subarachnoidal haemorrhage 1 
Bullet wound 1 
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Table 2: 
Procedures and reiections 
Maximal investigation 
Non-invasive intensive monitoring 8 
Semi-invasive monitoring (FOE, Pegs) 4 
Stereotaxic depth electrodes 3 
Rejected procedure 
Invasive monitoring 
Therapeutic intervention 
No specific proposal 
6 
6 
3 
Rejected by 
Patients and relatives 
Hospital team 
Consensus 
7 
6 
2 
No uniform treatment plan was followed as previ- 
ous investigations suggested taking individually dif- 
ferent routes. The primary therapeutic aim was still 
to render the patients free of all, or at least of all 
disabling, seizures. 
All seizures were documented in a seizure calendar 
differentiating between seizure types. Patients were 
usually seen in intervals of 3 months. Serum AED 
levels were determined for three reasons: to establish 
the individual pharmacokinetics of a given drug, to 
prove or refute possible toxicity, and following un- 
expected seizures to check for compliance problems 
and establish the individual therapeutic threshold. All 
other tests were done according to clinical necessity. 
As these are patients who had been considered for 
epilepsy surgery, it seems instructive to analyse them 
according to the scale which is most frequently used 
for the outcome measurement of operated patients’. 
This was slightly modified to meet the requirements 
of assessing people not surgically treated (Table 3). 
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Table 3: This scale was adapted from the classification of postoperative outcome of Engel er 01~ for patients without surgery, and 
possible inclusion of patients with generalized epilepsies. 
Classification of outcome with respect to seizures 
Class I: Free of disabling seizures 
A. Completely seizure free 
B. Non-disabling simple focal or non-convulsive generalized seizures only 
C. Isolated seizure with antiepileptic drug withdrawal only 
Class 11: Rare disabling seizures (‘almost’ seizure-free) 
A. Rare disabling seizures 
B. Nocturnal seizures only 
Class III: Worthwhile improvement 
A. Worthwhile seizure reduction a 
B. Prolonged seizure-free intervals amounting to greater than half the follow-up period, but not less than 2 years 
Class IV: No worthwhile improvement a 
A. Significant seizure reduction 
B. No appreciable change 
C. Seizures worse - 
a Determination of ‘worthwhile improvement’ will require quantitative analyses of additional data such as per cent seizure reduction. 
cognitive function, and quality of life. 
Table 4: 
Outcome of second-line pharmacotherapy 
Class I 
A. 3 patients 
B. 1 patient 
Class II 
A. I patient 
Class III 
A. 3 patients 
Class IV 
A. I patient 
B. 6 patients 
RESULTS 
The results are given in Table 4 where the patients 
are assigned to an outcome group according to the 12 
months preceding the last contact. Of the 15 patients, 
four (26.7%) belong to outcome group I as three are 
completely seizure free (IA), and one has no convul- 
sive seizures but only isolated auras (IB). One patient 
is in outcome group II (rare minimal focal seizures), 
and three are in group III, whereas seven patients 
(46.7%) are in group IV (one with moderate seizure 
reduction, and six unchanged). Of the unimproved 
patients, one has eventually accepted the proposed 
temporal lobectomy which was only partly success- 
ful (group IIIA with CP seizures in sleep, and isolated 
auras in the wake state). The case histories of the four 
patients in outcome group I are given below. 
(1) PF, a 50 year old housewife presented with sim- 
ple focal sensorimotor seizures of the left face and 
arm, sometimes evolving to generalized tonic-clonic 
(GTC) seizures. These had started during an acute 
febrile illness at age 45 (suspected encephalitis) and 
did not respond to monotherapies of phenytoin (DPH, 
intolerable side-effects reported at plasma level 
18.2 pg ml-‘), carbamazepine (CBZ, 11.6 @g ml-‘) 
and phenobarbital (PB, 34.0 p.g ml-‘). The reported 
side-effects were rather uncharacteristic, and the low 
tolerance seemed to suggest problems of coping with 
the illness. At non-invasive intensive monitoring sev- 
eral habitual focal seizures were recorded and were 
in favour of a right perirolandic origin. Semi-invasive 
monitoring with epidural peg electrodes was sug- 
gested as a next step of evaluation. For the first 
time, the patient realized the seriousness of the ill- 
ness, spontaneously increased her phenobarbital dose 
from 150 to 200 mg per day, and became seizure free 
at plasma levels of 40-45 pug ml-’ which were now 
well tolerated. Three years after the last seizure, dose 
reduction began, and the patient remained seizure free 
with a PB level of 28.6 p.g ml-’ at a daily dose of 
130 mg. 
(2) RL, a 49 year old deacon, developed crypto- 
genie epilepsy with both generalized and focal fea- 
tures at age 21. His seizure types were complex par- 
tial (CP), generalized clonic, and GTC. He had never 
received monotherapy but was treated with changing 
combinations of DPH, PB, primidone (PRM), CBZ, 
valproic acid (VPA) and clobazam (CLB). He was 
considered drug resistant, and had intensive moni- 
toring at a well-known centre for epilepsy surgery. 
A combination of foramen ovale and scalp elec- 
trodes revealed ictal onset with bilaterally symmetric 
Poly-Spike-Waves. It was proposed to try vigabatrine 
(VGB) and lamotrigine (LTG), and, in case of fail- 
ure, consider callosotomy. When I first saw him, both 
VGB and LTG had in turn been unsuccessfully added 
to a combination of PRM and CBZ. Detailed scrutiny 
of his case records revealed that, at an early stage, he 
had been seizure free for several years with a four- 
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Table 5: Table 6: 
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Successful treatments 
(groups I-III: N = 8) 
Monotherapies 3 (PB, VGB, bromide) 
2 AEDs 2 
3 AEDs 2 
4 AEDs 1 
Drugs involved in the combinations: 
Carbamazepine 3 
Phenobarbital, primidone 3 
Lamotrigine 2 
Valproic acid 2 
Vigabatrine 2 
Ethosuximide 1 
Phenvtoin 1 
drug combination of which all components but VPA 
had later unsuccessfully been used again. VPA was 
added to his baseline medication, and he has now 
been seizure free for more than 3 years. 
(3) JA, a 50 year old auctioneer had crypto- 
genie temporal lobe epilepsy since age 10, with CP 
seizures of increasing duration and complex automa- 
tisms. He was resistant to CBZ (16.0 pug ml-‘), 
DPH (25.3 pg ml-‘) and add-on medications 
of PB (22.5 pg ml-‘) and mesuximide (MS, 
32.5 ,ug ml-‘). Non-invasive intensive monitor- 
ing revealed bilateral temporal interictal and ic- 
tal epileptic foci, and PET scanning demonstrated 
massive bitemporal hypometabolism. The surgical 
indication was therefore considered to be highly 
problematic, and further drug trials recommended. 
Addition of VGB to a previous DPH monother- 
apy led to a drastic fall in seizure frequency. 
DPH was slowly withdrawn, and the patient be- 
came practically seizure free on VGB monother- 
apy. In 2 years, he has only had one cluster of 
SP and CP seizures at 4 g/day, and a single iso- 
lated aura at 5 g/day which he tolerates well. He 
has been completely seizure free for more than 12 
months. 
(4) UW, a 40 year old housewife, suffered from 
focal epilepsy since a right frontopolar haemorrhage 
from an angioma at age 32. Her seizure types were 
isolated auras with an illusion of movement, and 
secondarily generalized TC seizures with an initial 
version and elevation of her left arm, resulting in 
a habitual shoulder luxation. She was resistant to 
CBZ (12.4 kg ml-‘), DPH (45.4 kg ml-‘) and a PB 
add-on therapy (31.0 pg ml-‘). Two phases of non- 
invasive intensive monitoring gave no clues about 
the focus localization during the recorded isolated 
auras. No proposal for further procedures could be 
made. VGB was added to her regimen without effect, 
and withdrawn. Bromide was added, and her GTC 
seizures stopped. She is now on bromide monother- 
apy with serum levels of 1.0-1.2 mg ml-’ and has 
had no GTC seizures for the last 3 years. She has fre- 
Outcome in relation to diagnosis 
Diagnoses Successful Grow 1 
Temporal lobe epilepsy L 6 I 1 
of these, bilateral 3 I 1 
Extratemporal epilepsy 5 4 2 
Focal, unlocalized I - 
Focal and generalized signs 3 3 1 
Table 7: 
Employment status 
Outcome groups 
Present social condition I II III IV 
Adequately employed 51112 
In training 3--l 2 
Sheltered workshop l--l - 
Housewife, voluntary 22 --- 
Housewife, involuntary 2 - - - 2 
Invaliditv uension 21--l 
quent isolated auras which, however, she can easily 
cope with. 
When outcome classes I-III are considered together 
as ‘successful’ (n = 8) as opposed to unsuccessful 
(group IV, 12 = 7) therapies, it transpires that the suc- 
cessful regimens comprise such diverse concepts as 
monotherapies with high-level phenobarbital, vigaba- 
trine, and, of all things, bromide (an excellent drug for 
pharmacoresistant GTCS9), two two-drug, two three- 
drug and one four-drug combinations (Table 5). A 
total of nine different drugs were used on these eight 
patients without any unacceptable side-effects. 
A comparison of outcomes and types of epilepsy 
(Table 6) seems to indicate that patients with tempo- 
ral lobe epilepsy could be less successfully treated (i) 
than those with extratemporal epilepsies (i) or both 
focal and generalized features (i). The only case of 
clearly bitemporal epilepsy, however, made a very 
good outcome, and the apparent differences may be 
due to the small number of patients. 
The outcome of therapeutic interventions should 
not only refer to seizure control but also to quality 
of life. The relatively satisfactory pattern of employ- 
ment, even of the unsuccessfully treated patients of 
this group (Table 7), reflects the rehabilitation activi- 
ties of the providing epilepsy centre. Of the four pa- 
tients with an unsatisfactory vocational status (‘early 
pension’ or ‘involuntary housewife’), three are ther- 
apy resistant, and the one with successful treatment 
(case (3)) went into early retirement as a consequence 
of his seizures, before the successful therapy was 
found. 
DISCUSSION 
When the seizures of a patient with focal epilepsy re- 
sist treatment with a suitable drug of first choice, the 
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chances of obtaining seizure control with a change 
to another drug or a combination of two AEDs are 
in the order of lO-20% each”,“. Newly developed 
drugs at best make a similar addition to the rate of 
patients with complete seizure control. In most cen- 
tres, epilepsy surgery is today discussed after fail- 
ure of two to three appropriate AEDs because, then, 
the chances of therapy success are much higher with 
surgery than with pharmacotherapy, provided that the 
patients are properly selected. Thus, epilepsy surgery 
is not a ‘last hope’ for otherwise intractable patients 
as is sometimes suggested. It rather presents the pa- 
tient with a promising therapeutic alternative when 
the chances of relief from seizures by pharmacother- 
apy have become small and the further pursuit of 
pharmacological options must be expected to be time 
consuming and of uncertain outcome. 
In that situation, some patients will all the same 
prefer to continue with pharmacotherapy, and those 
who decide for a presurgical evaluation should know 
that, if no indication for surgery results, further phar- 
maceutical options exist. Until now, however, it is not 
possible to numerically specify the chances of such 
therapy if it comprises a whole sequence of treat- 
ments with drugs of second choice and variable AED 
combinations. 
The number of patients in this study is too small to 
provide reliable figures. One of the purposes of this 
paper is to draw attention to this problem and stimu- 
late more extensive research. The value of the study 
is in the fact that all patients have been treated by 
one epileptologist, in all but two cases both before 
and following a presurgical evaluation after which 
the surgical option was not pursued. In all but the 
stated two cases, the strictest criteria of AED resis- 
tance presently in use were fulfilled before the presur- 
gical evaluation. With regard to seizure types, focus 
localization and aetiologies, the patient group is fairly 
typical for the selection of patients monitored in our, 
and probably many other, centres. 
The outcome of conservative treatment in this small 
sample may not be representative, and too optimistic. 
A few conclusions, however, may be drawn. 
(1) Pharmacoresistance is not an absolute but a rel- 
ative concept. (2) There is probably no standard ther- 
apy for patients with focal epilepsies and a relatively 
high degree of pharmacoresistance. Often, individ- 
29 
ual strategies need to be developed which may prove 
highly rewarding. It can be useful to develop them 
on the background of earlier relative therapeutic suc- 
cesses in the same patient. (3) Complex empirical 
AED combinations are permissible therapies provided 
they are successful, and appropriate monotherapies 
have previously been tried. (4) Older and second-line 
drugs are by no means second-rate or obsolete. In the 
individual case, they may be more successful than 
first-line drugs. (5) The new AEDs will not solve all 
or most of the remaining problems of pharmacoresis- 
tance; they will, however, contribute to solve some. 
(6) A satisfactory vocational status as a measure of 
the quality of life does not necessarily depend upon 
a good therapeutic outcome, but seizure control is 
helpful. 
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